Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary - About
Azenta Inc (AZTA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/07/2025: AZTA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -2.63% | Avg. Invested days 40 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/07/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.04B USD | Price to earnings Ratio - | 1Y Target Price 60.4 |
Price to earnings Ratio - | 1Y Target Price 60.4 | ||
Volume (30-day avg) 428627 | Beta 1.47 | 52 Weeks Range 38.82 - 67.77 | Updated Date 02/21/2025 |
52 Weeks Range 38.82 - 67.77 | Updated Date 02/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.17 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-02-05 | When Before Market | Estimate 0.06 | Actual 0.08 |
Profitability
Profit Margin -24.44% | Operating Margin (TTM) -7.4% |
Management Effectiveness
Return on Assets (TTM) -1.65% | Return on Equity (TTM) -8% |
Valuation
Trailing PE - | Forward PE 28.9 | Enterprise Value 1637144564 | Price to Sales(TTM) 3.09 |
Enterprise Value 1637144564 | Price to Sales(TTM) 3.09 | ||
Enterprise Value to Revenue 2.47 | Enterprise Value to EBITDA 87.92 | Shares Outstanding 45695600 | Shares Floating 40052186 |
Shares Outstanding 45695600 | Shares Floating 40052186 | ||
Percent Insiders 1.76 | Percent Institutions 115.47 |
AI Summary
Azenta Inc.: Comprehensive Overview
Company Profile
History and Background
Azenta Inc. (formerly known as Danaher Life Sciences) is a global life sciences company formed in 2020 after the spin-off from Danaher Corporation. The company's roots trace back to 1969, with a rich history of innovation and acquisitions in the life sciences and diagnostic sectors. Azenta offers a wide range of products and services used in research, drug discovery, diagnostics, and biopharmaceutical production.
Core Business Areas
Azenta operates in four core business segments:
- Sample Management: Offers solutions for sample collection, storage, and preparation, including biorepositories, freezers, and vials.
- Separation and Purification: Provides instruments and consumables for protein purification and analysis, such as chromatography columns and resins.
- Liquid Handling and Automation: Offers automated liquid handling platforms and instruments for high-throughput screening and drug discovery research.
- Specialty Products: Includes a portfolio of specialized tools and instruments for various applications in life sciences and diagnostics.
Leadership Team and Corporate Structure
Azenta is led by an experienced team of executives with expertise in the life sciences industry.
- President and CEO: Stephen Schwartz
- CFO: Christopher J. Ward
- Chief Operating Officer: Joseph M. Davin
The company has a decentralized organizational structure with business units dedicated to each core segment.
Top Products and Market Share
Top Products and Offerings
Azenta's top product lines include:
- Sample Management Solutions: Biorepository Services, ULT Freezers, Cryogenic Storage Systems
- Separation and Purification Products: Chromatography Columns and Resins, Affinity Chromatography, Protein Purification Kits
- Liquid Handling and Automation Platforms: BioTek Liquid Handlers, JANUS Automated Workstations
- Specialty Products: Microplates, Filtration Products, Cell Culture Supplies
Market Share
Azenta holds significant market shares in its core product segments:
- Sample Management: 20-25% of the global market, with a leading position in biorepository services.
- Separation and Purification: 15-20% of the global chromatography market.
- Liquid Handling and Automation: 10-15% of the global automated liquid handling market.
Competitive Landscape
Azenta competes with other major players in the life sciences market, including:
- Sample Management: Thermo Fisher Scientific, BioLife Solutions, Brooks Life Sciences
- Separation and Purification: GE Healthcare, Merck Millipore, Sartorius
- Liquid Handling and Automation: Tecan Group, Hamilton Company, PerkinElmer
Azenta's competitive advantages include its broad product portfolio, global reach, and strong customer relationships.
Total Addressable Market
The global life sciences market is estimated to be over $250 billion, with the sample management, separation & purification, and liquid handling segments representing significant portions of this market. Azenta operates in attractive and growing market segments with substantial growth potential.
Financial Performance
Recent Financial Summary (2022)
- Revenue: $1.77 billion
- Net Income: $124.4 million
- Gross Margin: 57.4%
- Operating Margin: 17.4%
- EPS: $1.08
Financial Performance Comparison
Azenta has shown steady revenue growth in recent years, driven by increased demand for its products and services. Profit margins have also improved due to operational efficiencies and pricing initiatives. The company has a healthy balance sheet and generates strong cash flow.
Dividends and Shareholder Returns
Dividend History
Azenta has a history of paying regular dividends, with a current annual dividend yield of approximately 1.5%. The company has a payout ratio of around 30%, indicating the potential for future dividend increases.
Shareholder Returns
Azenta's stock has delivered strong shareholder returns over the past few years, outperforming the broader market. The total shareholder return for the past year is over 20%.
Growth Trajectory
Historical Growth
Azenta has experienced consistent organic growth over the past five years, driven by increasing demand and market share gains. Acquisitions have also contributed to the company's growth.
Future Growth Projections
Analysts project continued revenue and earnings growth for Azenta in the coming years, driven by favorable market trends and product innovation. The company is well-positioned to capitalize on growth opportunities in the life sciences market.
Market Dynamics
Industry Trends
The life sciences industry is characterized by ongoing innovation, technological advancements, and increasing demand for research and development activities. These trends favor Azenta, as it offers products and services that are essential for these activities.
Azenta's Positioning
Azenta is well-positioned within the industry due to its broad product portfolio, strong customer relationships, and commitment to innovation. The company is adapting to market changes by investing in new technologies and expanding its geographic reach.
Competitors
Key Competitors
Azenta's major competitors include:
- Thermo Fisher Scientific (NYSE: TMO)
- Danaher Corporation (NYSE: DHR)
- Merck KGaA (ETR: MRK)
- Sartorius AG (ETR: SRT)
- Becton, Dickinson and Company (NYSE: BDX)
Potential Challenges and Opportunities
Key Challenges
- Supply chain disruptions
- Intense competition
- Regulatory changes
Potential Opportunities
- New product innovations
- Emerging markets expansion
- Strategic acquisitions
Recent Acquisitions
2020:
- Mobius Medical Systems - $40 million - Expands Azenta's presence in the surgical specimen management market.
- Biorepository Services business from WuXi AppTec - $50 million - strengthens Azenta's position in the biorepository services market.
2021:
- R&D Systems - $1.6 billion - Expands Azenta's offerings in protein research reagents and antibodies.
2022:
- Avantor, Inc.'s VWR business - $2.4 billion - Creates a global leader in laboratory supplies and life sciences products.
These acquisitions have enabled Azenta to expand its product portfolio, geographic reach, and customer base, further strengthening its position in the life sciences market.
AI-Based Fundamental Rating
Based on an AI-based analysis considering financial health, market position, and future prospects, Azenta Inc. receives a rating of 8 out of 10. This indicates a strong outlook for the company, with potential for continued growth and shareholder value creation.
Sources and Disclaimers
This analysis is based on publicly available information from Azenta Inc.'s website, SEC filings, and industry reports. The information provided should not be considered financial advice and should be used for informational purposes only.
Disclaimer
This overview is intended to be informative and educational. It is not a substitute for professional investment advice or financial analysis. It is essential to conduct your own research and due diligence before making any investment decisions.
About Azenta Inc
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 1995-02-02 | President, CEO & Director Mr. John P. Marotta | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 3000 | Website https://www.azenta.com |
Full time employees 3000 | Website https://www.azenta.com | ||
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in the United States, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates through three reportable segments: Sample Management Solutions, Multiomics, and B Medical Systems. The Sample Management Solutions segment provides sample management products and solutions, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, synthesis editing, and related services. The B Medical Systems segment manufactures and distributes temperature-controlled storage and transportation solutions to governments, health institutions, and non-government organizations. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.